ENOV vs ATRC vs HOLX vs NVCR vs ABT

For growth investors, AtriCure, Inc.

(ATRC) is the stronger pick with 14. 9% revenue growth year-over-year, versus 1. 7% for Hologic, Inc. (HOLX). Abbott Laboratories (ABT) offers the better valuation at 11. 4x trailing P/E (15. 9x forward), making it the more compelling value choice. Analysts rate Enovis Corporation (ENOV) a "Buy" — based on 13 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Abbott Laboratories (ABT) is the cheapest at 11.

4x versus Hologic, Inc. at 30. 5x. On forward P/E, Enovis Corporation is actually cheaper at 7. 6x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, Hologic, Inc.

(HOLX) delivered a total return of +15. 8%, compared to -91. 3% for NovoCure Limited (NVCR). Over 10 years, the gap is even starker: ABT returned +173. 7% versus ENOV's -37. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Abbott Laboratories (ABT) is the lower-risk stock at 0.

25β versus NovoCure Limited's 2. 20β — meaning NVCR is approximately 788% more volatile than ABT relative to the S&P 500. On balance sheet safety, AtriCure, Inc. (ATRC) carries a lower debt/equity ratio of 18% versus 92% for Enovis Corporation — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), AtriCure, Inc.

(ATRC) is pulling ahead at 14. 9% versus 1. 7% for Hologic, Inc. (HOLX). On earnings-per-share growth, the picture is similar: Abbott Laboratories grew EPS 133. 6% year-over-year, compared to -39. 7% for Enovis Corporation. Over a 3-year CAGR, ATRC leads at 17. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Abbott Laboratories (ABT) is the more profitable company, earning 31.

9% net margin versus -52. 7% for Enovis Corporation — meaning it keeps 31. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: HOLX leads at 17. 4% versus -52. 6% for ENOV. At the gross margin level — before operating expenses — NVCR leads at 74. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Enovis Corporation (ENOV) trades at 7.

6x forward P/E versus 370. 7x for AtriCure, Inc. — 363. 1x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for NVCR: 99. 0% to $33. 50.

In this comparison, ABT (2.

5% yield) pays a dividend. ENOV, ATRC, HOLX, NVCR do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Abbott Laboratories (ABT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

25), 2. 5% yield, +173. 7% 10Y return). Enovis Corporation (ENOV) carries a higher beta of 2. 05 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ABT: +173. 7%, ENOV: -37. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (ENOV (Industrials) and ATRC (Healthcare) and HOLX (Healthcare) and NVCR (Healthcare) and ABT (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: ENOV is a small-cap quality compounder stock; ATRC is a small-cap quality compounder stock; HOLX is a mid-cap quality compounder stock; NVCR is a small-cap quality compounder stock; ABT is a mid-cap deep-value stock. ABT pays a dividend while ENOV, ATRC, HOLX, NVCR do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.